Cyanonilutamide

Cyanonilutamide
Clinical data
Other names	RU-56279
Drug class	Nonsteroidal antiandrogen
Identifiers
	IUPAC name 4-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile;
CAS Number	143782-20-1 ;
PubChem CID	11162285;
ChemSpider	9337385;
UNII	6PAG4TC385;
ChEMBL	ChEMBL146858;
CompTox Dashboard (EPA)	DTXSID901143349 ;
Chemical and physical data
Formula	C13H10F3N3O2
Molar mass	297.237 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)C#N)C(F)(F)F)C;
	InChI InChI=1S/C13H10F3N3O2/c1-12(2)10(20)19(11(21)18-12)8-4-3-7(6-17)9(5-8)13(14,15)16/h3-5H,1-2H3,(H,18,21); Key:CYCKLVAQENOQPG-UHFFFAOYSA-N;

Cyanonilutamide (developmental code name RU-56279) is a nonsteroidal antiandrogen which was never marketed.^[1]^[2] Both RU-56187 and RU-58841 appear to be prodrugs of cyanonilutamide in vivo in animals.^[2] It has relatively low affinity for the androgen receptor but nonetheless shows significant antiandrogenic activity in animals.^[2]

References

^ Gryder BE, Akbashev MJ, Rood MK, Raftery ED, Meyers WM, Dillard P, Khan S, Oyelere AK (November 2013). "Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors". ACS Chem. Biol. 8 (11): 2550–60. doi:10.1021/cb400542w. PMC 3836611. PMID 24004176.
^ ^a ^b ^c Cousty-Berlin D, Bergaud B, Bruyant MC, Battmann T, Branche C, Philibert D (October 1994). "Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite". J. Steroid Biochem. Mol. Biol. 51 (1–2): 47–55. doi:10.1016/0960-0760(94)90114-7. PMID 7947350. S2CID 29752252.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.